Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 11/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845972 | 1.00 | PSMB5 (0.55) | PSMB5PSMB8KDM4EKMT2AHTT | |
| SCHEMBL13845899 | 0.88 | PSMB5 (0.61) | PSMB5PSMB8SMN1; SMN2PKMMRGPRX4 | |
| SCHEMBL3653865 | 0.88 | PSMB5 (0.60) | PSMB5PSMB8SMN1; SMN2PKMMRGPRX4 | |
| SCHEMBL3662229 | 0.88 | PSMB5 (0.61) | PSMB5PSMB8SMN1; SMN2PKMMRGPRX4 | |
| SCHEMBL13846026 | 0.88 | PSMB5 (0.60) | PSMB5PSMB8SMN1; SMN2PKMMRGPRX4 | |
| SCHEMBL13846042 | 0.88 | PSMB5 (0.68) | PSMB5PSMB8 | |
| SCHEMBL3659451 | 0.88 | PSMB5 (0.68) | PSMB5PSMB8 | |
| SCHEMBL3655369 | 0.86 | PSMB5 (0.61) | PSMB5PSMB8KMT2ASMN1; SMN2PKM | |
| SCHEMBL13845967 | 0.86 | PSMB5 (0.61) | PSMB5PSMB8KMT2ASMN1; SMN2PKM | |
| SCHEMBL13845897 | 0.83 | PSMB5 (0.61) | PSMB5PSMB8MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PSMB5 1165/4885PSMB8 1092/4885KDM4E 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.